Product Description
MM-110 has a novel Mechanism to Address a Critical Gap in OUD Treatment. (Sourced from: https://mindmed.co/programs-research/#scroll_section-2)
Mechanisms of Action: nAChR Antagonist
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mind Medicine
Company Location: VANCOUVER A1 V6E 3Z3
Company CEO: Robert Barrow
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Opioid-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|